Platinum-containing regimens and/or poly (ADP-ribose) polymerase (PARP) inhibitors are reported to be more effective against hereditary pancreatic cancer than against sporadic pancreatic cancer. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.